Proliferative activity of osteosarcoma cells: Comparison of osteoblastic and nonosteoblastic regions

Journal of Orthopaedic Science

Volumn 8, Issue 5, 2003, Pages 678-682

  Sakayama, Kenshi ^a   Fujibuchi, Taketsugu ^a   Kidani, Teruki ^a   Miyazaki, Tatsuhiko ^a   Yamamoto, Haruyasu ^a  

^a EHIME UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Argyrophilic nucleolar organizer regions (AgNORs); Osteosarcoma; Proliferating cell nuclear antigen (PCNA)

Indexed keywords

CISPLATIN; CYCLINE; DNA DIRECTED RNA POLYMERASE; DNA POLYMERASE; DOXORUBICIN; METHOTREXATE; RIBOSOME DNA; RIBOSOME RNA;

ADOLESCENT; ADULT; ARTICLE; CELL PROLIFERATION; CHROMOSOME NOR; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MALE; OSTEOBLAST; OSTEOSARCOMA; OSTEOSARCOMA CELL;

EID: 0142026473     PISSN: 09492658     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00776-003-0694-y     Document Type: Article

References (30)

1. Baldini N, Scotlandi K, Barbanti-Brodano IG, et al. Expression of P-glycoprotein in high-grade osteosarcoma in relation to clinical outcome. N Engl J Med 1995;333:1380-5.
2. Bravo R, Fey SJ, Bellatin J, et al. Identification of nuclear and of a cytoplasmic polypeptide whose relative proportions are sensitive to changes in the rate of cell proliferation. Exp Cell Res 1981;136:311-9.
3. Bravo R, Frank R, Blundel PA, et al. Cyclin/PCNA is the auxiliary protein of DNA polimerase-6. Nature 1987;326:515-7.
4. Chano T, Matsumoto K, Ishizawa M, et al. Analysis of the presence of osteocalcin, S-100 protein, and proliferating cell nuclear antigen in cells of various types of osteosarcomas. Eur J Histochem 1996;40:189-98.
5. Clohisy JC, Schajowicz F, Vaziri DM, et al. Assessment of argyrophilic nucleolar organizer region quantification in benign and malignant bone tumor. Clin Orthop 1995;310:229-36.
6. Davis AM, Bell RS, Goodwin PJ. Prognostic factors in osteosarcoma: a critical review. J Clin Oncol 1994;12:423-31.
7. Enneking WF, Spanier SS, Goodman MA. A system for the surgical staging of musculoskeletal sarcoma. Clin Orthop 1980; 153:106-20.
8. Garcia RL, Coltrera MD, Gown AM. Analysis of proliferative grade using anti-PCNA/cyclin monoclonal antibodies in fixed, embedded tissues: comparison with flow cytometric analysis. Am J Pathol 1989;134:733-9.
9. Ghazizadeh M, Sasaki Y, Araki T, et al. Prognostic value of proliferative activity of ovarian carcinoma as revealed by PCNA and AgNOR analysis. Am J Clin Pathol 1997;107:451-8.
10. Glasser DB, Lane JM, Huvos AG, et al. Survival, prognosis, and therapeutic response in osteogenic sarcoma: the Memorial Hospital experience. Cancer 1992;69:698-708.
11. Ishida T, Kaneko S, Akazawa K, et al. Proliferating cell nuclear antigen expression and argyrophilic nucleolar organizer regions as factors influencing prognosis of surgically treated lung cancer patients. Cancer Res 1993;53:5000-3.
12. Kuratsu S, Aozasa K, Myoui A, et al. Prognostic significance of argyrophilic nucleolar organizer staining in soft-tissue sarcomas. Int J Cancer 1991;48:211-4.
13. Lin J, Leung W, Ho SKW, et al. Quantitive evaluation of thallium-201 uptake in predicting chemotherapeutic response of osteosarcoma. Eur J Nucl Med 1995;22:553-5.
14. Linder NJ, Scarborough MT, Spanier SS, et al. Local host response in osteosarcoma after chemotherapy referred to radiographs, CT, tumour necrosis and patient survival. J Cancer Res Clin Oncol 1998;124:575-80.
15. Login GR, Galli SJ, Morgan E, et al. Rapid microwave fixation of rat mast cells. Lab Invest 1987;57:592-9.
16. Login GR, Schnitt SJ, Dvorak AM. Methods in laboratory investigation. Lab Invest 1987;57:585-91.
17. Miyachi K, Fritzler MJ, Tan EM. Autoantibody to a nuclear antigen in proliferating cells. J Immunol 1978;121:2228-34.
18. Ohno T, Tanaka T, Takeuchi S, et al. Nucleolar organizer regions in bone tumors. Clin Orthop 1991;272:287-91.
19. Okada K, Nishida J, Morita T, et al. Low-grade intraosseous osteosarcoma in northern Japan: advantage of AgNOR and MIB-1 staining in differential diagnosis. Hum Pathol 2000;31:633-9.
20. Ongolo-Zogo P, Thiesse P, Sau J, et al. Assenssment of osteosarcoma response to neoadjuvant chemotherapy: comparative usefulness of dynamic gadolium-enhanced spin-echo magnetic resonance imaging and technecium-99m skeletal angioscintigraphy. Eur Radiol 1999;9:907-14.
21. Picci P, Sangiorgi L, Rougraff BT, et al. Relationship of chemotherapy-induced necrosis and surgical margins to local recurrence in osteosarcoma. J Clin Oncol 1994;12:2699-705.
22. Ploton D, Menager M, Jeannesson P, et al. Improvement in the staining and in the visualization of the argyrophilic proteins of the nucleolar organizer region at the optical level. Histochem J 1986;18:5-14.
23. Radig K, Häckel C, Herting J, et al. Expression of P-glycoprotein in high grade osteosarcomas with special emphasis on chondroblastic subtype. Gen Diagn Pathol 1997;142:139-45.
24. Robbins BA, de la Vega D, Ogata K, et al. Immunohistochemical detection of proliferating cell nuclear antigen in solid human malignancies. Arch Pathol Lab Med 1987;111:841-5.
25. Rosen G, Caparros B, Huvos AG, et al. Preoperative chemotherapy for osteogenic sarcoma: selection of postoperative adjuvant chemotherapy based on the response of the primary tumor to preoperative chemotherapy. Cancer 1982;49:1221-30.
26. Sakayama K, Masuno H, Miyazaki T, et al. Existence of lipoprotein lipase in human sarcomas and carcinomas. Jpn J Cancer Res 1994;85:515-21.
27. Schwint AE, Araujo ES, Cole A, et al. Nucleolar organizer regions in parosteal and central osteosarcomas. Clin Orthop 1996;327:253-8.
28. Thiebaut F, Rigaut JP, Reith A. Improvement in the specificity of the silver staining technique for AgNOR-associated acidic proteins in paraffin sections. Stain Technol 1984;59:181-5.
29. Waseem NH, Lane DP. Monoclonal antibody analysis of the proliferating cell nuclear antigen (PCNA). J Cell Sci 1990;96:121-9.
30. Wellings RM, Davies AM, Pynsent PB, et al. The value of computed tomographic measurements in osteosarcoma as a predictor of response to adjuvant chemotherapy. Clin Radiol 1994;49:19-23.